An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment
The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment with secukinumab, and are unable to obtain the marketed secukinumab formulation.
Inclusion Criteria:
Exclusion Criteria:
novartis.email@novartis.com1-888-669-6682
+41613241111
Voorhees Township, New Jersey 08043, United States
Bogota, Cundinamarca 110221, Colombia
Brno-Zidonice, CZE 61500, Czechia
Culiacan, State of Mexico 80000, Mexico
Panorama, Western Cape 7500, South Africa
Santiago Compostela, A Coruna 15706, Spain
Heathrah17@yahoo.com+1 561 361 6547
william.johnston@orlandohealth.com+1 813 782 1234